Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2017-09-04
Target enrollment:
Participant gender:
Summary
This pilot phase II trial studies how well vincristine sulfate liposome works in treating
patients with acute myeloid leukemia that has returned after a period of improvement or has
not responded to previous treatment. Drugs used in chemotherapy, such as vincristine sulfate
liposome, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Liposomal
encapsulation prolongs bioavailability (proportion of drug that enters the circulation when
introduced into the body) of vincristine sulfate, and may increase its delivery to cancer
cells with fewer side effects.
Phase:
Phase 2
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborators:
National Cancer Institute (NCI) Spectrum Pharmaceuticals, Inc